Aztreonam lysine: a novel inhalational antibiotic for cystic fibrosis

References

• Ratjen F. Update in cystic fibrosis 2008. Am. J. Respir. Crit. Care Med.179(6), 445–448 (2009).
   PubMed Web of Science ®Google Scholar
• Razvi S, Quittell L, Sewall A, Quinton H, Marshall B, Saiman L. Respiratory microbiology of patients with cystic fibrosis in the United States, 1995–2005. Chest136(6), 1554–1560 (2009).
   PubMed Web of Science ®Google Scholar
• Lambiase A, Raia V, Del Pezzo M, Sepe A, Carnovale V, Rossano F. Microbiology of airway disease in a cohort of patients with cystic fibrosis. BMC Infect. Dis.6, 4 (2006).
   PubMed Web of Science ®Google Scholar
• Li Z, Kosorok MR, Farrell PM et al. Longitudinal development of mucoid Pseudomonas aeruginosa infection and lung disease progression in children with cystic fibrosis. JAMA293(5), 581–588 (2005).
   PubMed Web of Science ®Google Scholar
• Kerem E, Corey M, Gold R, Levison H. Pulmonary function and clinical course in patients with cystic fibrosis after pulmonary colonization with Pseudomonas aeruginosa. J. Pediatr.116(5), 714–719 (1990).
   PubMed Web of Science ®Google Scholar
• Flume PA, Mogayzel PJ, Robinson KA et al. Cystic fibrosis pulmonary guidelines: treatment of pulmonary exacerbations. Am. J. Respir. Crit. Care Med.180(9), 802–808 (2009).
   PubMed Web of Science ®Google Scholar
• Smyth A, Elborn JS. Exacerbations in cystic fibrosis: 3 – management. Thorax63(2), 180–184 (2008).
   PubMed Web of Science ®Google Scholar
• Szaff M, Hoiby N, Flensborg EW. Frequent antibiotic therapy improves survival of cystic fibrosis patients with chronic Pseudomonas aeruginosa infection. Acta Paediatr. Scand.72(5), 651–657 (1983).
   PubMed Web of Science ®Google Scholar
• Elborn JS, Prescott RJ, Stack BH et al. Elective versus symptomatic antibiotic treatment in cystic fibrosis patients with chronic Pseudomonas infection of the lungs. Thorax55(5), 355–358 (2000).
   PubMed Web of Science ®Google Scholar
• di Sant Agnese PA, Anderson D. Chemotherapy in infections of the respiratory tract associated with cystic fibrosis of the pancreas; observations with penicillin and drugs of the sulfonamide group, with special reference to penicillin aerosol. Am. J. Dis. Child.72, 17–61 (1946).
   Google Scholar
• Kuhn RJ. Formulation of aerosolized therapeutics. Chest120(3 Suppl.), 94S–98S (2001).
   PubMed Web of Science ®Google Scholar
• Ramsey BW, Pepe MS, Quan JM et al. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group. N. Engl. J. Med.340(1), 23–30 (1999).
   PubMed Web of Science ®Google Scholar
• Moskowitz SM, Silva SJ, Mayer-Hamblett N et al. Shifting patterns of inhaled antibiotic use in cystic fibrosis. Pediatr. Pulmonol.43(9), 874–881 (2008).
   PubMed Web of Science ®Google Scholar
• LiPuma JJ. Microbiological and immunologic considerations with aerosolized drug delivery. Chest120(3 Suppl.), 118S–123S (2001).
   Web of Science ®Google Scholar
• McCoy KS, Quittner AL, Oermann CM, Gibson RL, Retsch-Bogart GZ, Montgomery AB. Inhaled aztreonam lysine for chronic airway Pseudomonasaeruginosa in cystic fibrosis. Am. J. Respir. Crit. Care Med.178(9), 921–928 (2008).
   PubMed Web of Science ®Google Scholar
• Retsch-Bogart GZ, Quittner AL, Gibson RL et al. Efficacy and safety of inhaled aztreonam lysine for airway Pseudomonas in cystic fibrosis. Chest135(5), 1223–1232 (2009).
   PubMed Web of Science ®Google Scholar
• Cystic Fibrosis Trust. UK CF Registry Annual Data Report 2008. Cystic Fibrosis Trust, Kent, UK (2009).
   Google Scholar
• Sawicki GS, Sellers DE, Robinson WM. High treatment burden in adults with cystic fibrosis: challenges to disease self-management. J. Cyst. Fibrosis8(2), 91–96 (2009).
   PubMed Web of Science ®Google Scholar
• Orlicek SL. Aztreonam. Semin. Pediatr. Infect. Dis.10(1), 45–50 (1999).
   Google Scholar
• Cullman W, Buscher KH, Dick W. Selection and properties of Pseudomonas aeruginosa variants resistant to β-lactam antibiotics. Eur. J. Clin. Microbiol.6(4), 467–473 (1987).
   PubMedGoogle Scholar
• Vedel G. Simple method to determine β-lactam resistance phenotypes in Pseudomonasaeruginosa using the disc agar diffusion test. J. Antimicrob. Chemother.56(4), 657–664 (2005).
   PubMedGoogle Scholar
• Hocquet D, Berthelot P, Roussel-Delvallez M et al.Pseudomonas aeruginosa may accumulate drug resistance mechanisms without losing its ability to cause bloodstream infections. Antimicrob. Agents Chemother.51(10), 3531–3536 (2007).
   PubMedGoogle Scholar
• Quale J, Bratu S, Gupta J, Landman D. Interplay of efflux system, ampC, and oprD expression in carbapenem resistance of Pseudomonas aeruginosa clinical isolates. Antimicrob. Agents Chemother.50(5), 1633–1641 (2006).
   PubMed Web of Science ®Google Scholar
• Shawar RM, MacLeod DL, Garber RL et al. Activities of tobramycin and six other antibiotics against Pseudomonas aeruginosa isolates from patients with cystic fibrosis. Antimicrob. Agents Chemother.43(12), 2877–2880 (1999).
   PubMedGoogle Scholar
• Dietzsch HJ, Gottschalk B, Heyne K, Leupoid W, Wunderlich P. Cystic fibrosis: comparison of two mucolytic drugs for inhalation treatment (acetylcysteine and arginine hydrochloride). Pediatrics55(1), 96–100 (1975).
   PubMedGoogle Scholar
• Keller M, Hug M, Bietterle E, Bucholski A. Reduced treatment time for colistinmethate sodium solutions (colistin CF) aerosolized by eFlow rapid, a novel electronic nebulizer. Presented at: 29th European Cystic Fibrosis Conference. Copenhagen, Denmark, 15–18 June 2006.
   Google Scholar
• Collins N. Nebulizer therapy in cystic (Suppl. 1), 11–17 (2009).
   Google Scholar
• Gibson RL, Retsch-Bogart GZ, Oermann C et al. Microbiology, safety, and pharmacokinetics of aztreonam lysinate for inhalation in patients with cystic fibrosis. Pediatr. Pulmonol.41(7), 656–665 (2006).
   PubMed Web of Science ®Google Scholar
• Mendelman PM, Smith AL, Levy J, Weber A, Ramsey B, Davis RL. Aminoglycoside penetration, inactivation, and efficacy in cystic fibrosis sputum. Am. Rev. Respir. Dis.132(4), 761–765 (1985).
   PubMed Web of Science ®Google Scholar
• Rosenfeld M, Gibson R, McNamara S et al. Serum and lower respiratory tract drug concentrations after tobramycin inhalation in young children with cystic fibrosis. J. Pediatr.139(4), 572–577 (2001).
   PubMed Web of Science ®Google Scholar
• Bucholski A, Keller M, Balcke A et al.In vitro performance of eFlow™, an electronic inhaler for administration of a novel aztreonam formulation to CF patients. Pediatr. PulmonologyS25(37), 321 (2003).
   Google Scholar
• Mihindu JC, Scheld WM, Bolton ND, Spyker DA, Swabb EA, Bolton WK. Pharmacokinetics of aztreonam in patients with various degrees of renal dysfunction. Antimicrob. Agents Chemother.24(2), 252–261 (1983).
   PubMed Web of Science ®Google Scholar
• Saxon A, Hassner A, Swabb EA, Wheeler B, Adkinson NF Jr. Lack of cross-reactivity between aztreonam, a monobactam antibiotic, and penicillin in penicillin-allergic subjects. J. Infect. Dis.149(1), 16–22 (1984).
   PubMed Web of Science ®Google Scholar
• Saxon A, Swabb EA, Adkinson NF Jr. Investigation into the immunologic cross-reactivity of aztreonam with other β-lactam antibiotics. Am. J. Med.78(2A), 19–26 (1985).
   PubMed Web of Science ®Google Scholar
• Jensen T, Pedersen SS, Hoiby N, Koch C. Safety of aztreonam in patients with cystic fibrosis and allergy to β-lactam antibiotics. Rev. Infect. Dis.13(Suppl. 7), S594–S597 (1991).
   Google Scholar
• Retsch-Bogart GZ, Burns JL, Otto KL et al. A Phase 2 study of aztreonam lysine for inhalation to treat patients with cystic fibrosis and Pseudomonas aeruginosa infection. Pediatr. Pulmonol.43(1), 47–58 (2008).
   PubMed Web of Science ®Google Scholar
• Oermann CM, McCoy KS, Retsch-Bogart GZ, Gibson RL, Montgomery AB. Effect of multiple courses of aztreonam lysine for inhalation (AZLI) on FEV1 and weight in patients with cystic fibrosis (CF) and Pseudomonas aeruginosa (PA): analysis of 18 month data from CP-AI-006. J. Cyst. Fibrosis8(Suppl. 2), S28 (2009).
   Google Scholar
• Oermann CM R-BG, McCoy KS, Gibson RL, Quittner AL, Montgomery AB. Adherence over multiple courses of aztreonam lysine for inhalation (AZLI): effect on disease related endpoints in patients with cystic fibrosis (CF) and Pseudomonas aeruginosa (PA). Pediatr. Pulmonology44(Suppl. 32), 296 (2009).
   Google Scholar
• Quittner AL, Buu A, Messer MA, Modi AC, Watrous M. Development and validation of The Cystic Fibrosis Questionnaire in the United States: a health-related quality-of-life measure for cystic fibrosis. Chest128(4), 2347–2354 (2005).
   PubMed Web of Science ®Google Scholar
• Quittner AL, Modi AC, Wainwright C, Otto K, Kirihara J, Montgomery AB. Determination of the minimal clinically important difference scores for the cystic fibrosis questionnaire-revised respiratory symptom scale in two populations of patients with cystic fibrosis and chronic Pseudomonas aeruginosa airway infection. Chest135(6), 1610–1618 (2009).
   PubMed Web of Science ®Google Scholar
• Oermann CM, McCoy KS, Retsch-Bogart GZ, Gibson RL, Quittner AL, Montgomery AB. Effect of multiple aztreonam lysine for inhalation (AZLI) cycles on disease-related endpoints and safety in patients with cystic fibrosis (CF) and Pseudomonas aeruginosa (PA): interim analysis of 12 month data. J. Cyst. Fibrosis7(S2), S25 (2008).
   Google Scholar
• Oermann CM, McCoy KS, Retsch-Bogart GZ, Gibson RL, McKevitt M. Montgomery AB. Effect of repeated exposure to aztreonam for inhalation solution (AZLI) therapy on cystic fibrosis respiratory pathogens. Pediatr. Pulmonol.44(Suppl. 32), S335 (2009).
   Google Scholar
• Oermann CM, McCoy KS, Retsch-Bogart GZ, Gibson RL, McKevitt M, Montgomery AB. Antibiotic susceptibility in Pseudomonas aeruginosa (PA) isolates following repeated exposure to aztreonam for inhalation solution (AZLI) in patients with cystic fibrosis. Pediatr. Pulmonology44(Suppl. 32), 309 (2009).
   PubMedGoogle Scholar
• Hodson ME, Gallagher CG, Govan JR. A randomised clinical trial of nebulised tobramycin or colistin in cystic fibrosis. Eur. Respir. J.20(3), 658–664 (2002).
   PubMed Web of Science ®Google Scholar
• Adeboyeku D, Scott S, Hodson ME. Open follow-up study of tobramycin nebuliser solution and colistin in patients with cystic fibrosis. J. Cyst. Fibrosis5(4), 261–263 (2006).
   PubMed Web of Science ®Google Scholar
• Montgomery AB, Lewis S, Higuchi K, Marshall B, Oermann C. Hospitalization risk of current standard of care (SOC) vs aztreonam for inhalation solution (AZLI) in patients with cystic fibrosis (CF). Am. J. Respir. Crit. Care Med.179, A1188 (2009).
   Google Scholar
• Flume PA, O’Sullivan BP, Robinson KA et al. Cystic fibrosis pulmonary guidelines: chronic medications for maintenance of lung health. Am. J. Respir. Crit. Care Med.176(10), 957–969 (2007).
   PubMed Web of Science ®Google Scholar
• Saini SD, Schoenfeld P, Kaulback K, Dubinsky MC. Effect of medication dosing frequency on adherence in chronic diseases. Am. J. Manag. Care15(6), e22–e33 (2009).
   PubMed Web of Science ®Google Scholar
• Ratjen F, Rietschel E, Kasel D et al. Pharmacokinetics of inhaled colistin in patients with cystic fibrosis. J. Antimicrob. Chemother.57(2), 306–311 (2006).
   PubMed Web of Science ®Google Scholar
• Rottier BL, van Erp CJ, Sluyter TS, Heijerman HG, Frijlink HW, Boer AH. Changes in performance of the Pari eFlow rapid and Pari LC Plus during 6 months use by CF patients. J. Aerosol Med. Pulm. Drug Deliv.22(3), 263–269 (2009).
   PubMed Web of Science ®Google Scholar
• Oermann CM, McCoy KS, Retsch-Bogart GZ. Gibson RL, Quittner AL, Montgomery AB. Adherence over multiple courses of aztreonam lysine for inhalation (AZLI): effect on disease-related endpoints in patients with cystic fibrosis (CF) and Pseudomonas aeruginosa (PA). J. Cyst. Fibrosis8(2 Suppl.), S28 (2009).
   Google Scholar
• Chuchalin A, Csiszer E, Gyurkovics K et al. A formulation of aerosolized tobramycin (Bramitob) in the treatment of patients with cystic fibrosis and Pseudomonas aeruginosa infection: a double-blind, placebo-controlled, multicenter study. Paediatr. Drugs9(Suppl. 1), 21–31 (2007).
   PubMedGoogle Scholar
• Sabet M, Miller CE, Nolan TG, Senekeo-Effenberger K, Dudley MN, Griffith DC. Efficacy of aerosol MP-376, a levofloxacin inhalation solution, in models of mouse lung infection due to Pseudomonas aeruginosa. Antimicrob. Agents Chemother.53(9), 3923–3928 (2009).
   PubMed Web of Science ®Google Scholar
• Li Z, Zhang Y, Wurtz W et al. Characterization of nebulized liposomal amikacin (Arikace) as a function of droplet size. J. Aerosol. Med. Pulm. Drug Deliv.21(3), 245–254 (2008).
   PubMed Web of Science ®Google Scholar
• Okusanya OO, Bhavnani SM, Hammel J et al. Pharmacokinetic and pharmacodynamic evaluation of liposomal amikacin for inhalation in cystic fibrosis patients with chronic pseudomonal infection. Antimicrob. Agents Chemother.53(9), 3847–3854 (2009).
   PubMed Web of Science ®Google Scholar
• Geller DE, Konstan MW, Smith J, Noonberg SB, Conrad C. Novel tobramycin inhalation powder in cystic fibrosis subjects: pharmacokinetics and safety. Pediatr. Pulmonol.42(4), 307–313 (2007).
   PubMed Web of Science ®Google Scholar
• Stass H, Nagelschmitz J, Posselt H. Safety, tolerability and pharmacokinetics of ciprofloxacin dry powder inhalation in adolescent patients with CF. Pediatr. Pulmonol.44(Suppl. 32), 302 (2009).
   Google Scholar
• Westerman EM, De Boer AH, Le Brun PP et al. Dry powder inhalation of colistin in cystic fibrosis patients: a single dose pilot study. J. Cyst. Fibrosis6(4), 284–292 (2007).
   PubMed Web of Science ®Google Scholar
• MacLeod DL, Barker LM, Sutherland JL et al. Antibacterial activities of a fosfomycin/tobramycin combination: a novel inhaled antibiotic for bronchiectasis. J. Antimicrob. Chemother.64(4), 829–836 (2009).
   PubMed Web of Science ®Google Scholar
• Ratjen F, Munck A, Kho P, Angyalosi G. Treatment of early Pseudomonas aeruginosa infection in patients with cystic fibrosis: the ELITE trial. Thorax65(4), 286–291 (2009).
   PubMedGoogle Scholar
• Treggiari MM, Rosenfeld M, Mayer-Hamblett N et al. Early anti-pseudomonal acquisition in young patients with cystic fibrosis: rationale and design of the EPIC clinical trial and observational study. Contemp. Clin. Trials30(3), 256–268 (2009).
   PubMed Web of Science ®Google Scholar
• Lebecque P, Leal T, Zylberberg K, Reychler G, Bossuyt X, Godding V. Towards zero prevalence of chronic Pseudomonas aeruginosa infection in children with cystic fibrosis. J. Cyst. Fibrosis5(4), 237–244 (2006).
   PubMedGoogle Scholar
• Prober CG, Walson PD, Jones J. Technical report: precautions regarding the use of aerosolized antibiotics. Committee on Infectious Diseases and Committee on Drugs. Pediatrics106(6), e89 (2000).
   PubMed Web of Science ®Google Scholar
• Merlo CA, Boyle MP, Diener-West M, Marshall BC, Goss CH, Lechtzin N. Incidence and risk factors for multiple antibiotic-resistant Pseudomonas aeruginosa in cystic fibrosis. Chest132(2), 562–568 (2007).
   PubMedGoogle Scholar
• Hamblett NM, Retsch-Bogart GZ, Treggiari M et al. Safety and efficacy of anti-pseudomonal therapy for early eradication of Pseudomonas: the EPIC study. Pediatr. Pulmonology44(Suppl. 32), 183 (2009).
   PubMedGoogle Scholar
• Sykes RB, Bonner DP. Aztreonam: the first monobactam. Am. J. Med.78(2 Suppl. 1), 2–10 (1985).
   PubMedGoogle Scholar